Business
Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer
SAN JOSE, Calif., Sept. 7, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"SAN JOSE, Calif., Sept. 7, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today the appointment of Pamela D. Garzone, Ph.D., as Chief Development Officer. Dr. Garzone will oversee Anixa's vaccine and therapeutic development programs and will report to the CEO. \n\n \n \n \n \n \n \n\n \n\"We are pleased to have Dr. Garzone join Anixa at this pivotal and exciting time for the company,\" stated Dr. Amit Kumar, President and CEO of Anixa Biosciences. \"Pam's clinical experience will be instrumental as we enter clinical trials with our preventative breast cancer vaccine and our ovarian cancer CAR-T treatment.\" \nDr. Garzone is a senior pharmaceutical executive with over 25 years of diverse experience in the industry and is recognized for her strategic, scientific, clinical and regulatory leadership in drug development. Prior to joining Anixa, Dr. Garzone held executive roles in clinical development with several companies, including Calibr, a division of the Scripps Research Institute, and Pfizer. She previously held positions of increasing responsibility at companies such as Elan Pharmaceuticals and Genetics Institute, starting her industry career at Genentech. Prior to her industry experience, she was an Assistant Professor, Pharmacy and Therapeutics at the University of Pittsburgh School of Pharmacy. She earned a B.S. degree in Pharmacy from Purdue University and an M.S. in Pharmacy Practice from the University of Pittsburgh. She received her Ph.D. in Clinical Science from the University of Pittsburgh. In 2019, she was awarded the Distinguished Alumnus of University of Pittsburgh School of Pharmacy.\nDr. Garzone stated, \"I am excited and honored to join the team at Anixa, as the company transitions from a pre-clinical company to a clinical company. I am looking forward to helping advance Anixa's programs, especially the breast cancer vaccine which is about to enter clinical trials shortly.\" \nAbout Anixa Biosciences, Inc.Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology,...